alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1099 Tartaric acid. ( a ) Food grade tartaric acid (C4H6O6, CAS Reg. No. 87-69-4) has the l configuration. The l form of tartaric acid is dextrorotatory in solution and is also known as l−(+)−tartaric acid. Tartaric acid occurs as colorless or translucent crystals or as a white, crystalline powder. It is odorless and has an acid taste. It is obtained as a byproduct of wine manufacture.
( b ) The ingredient meets the specifications of the Food Chemicals Codex, 3d Ed. (1981), P. 320, which is incorporated by reference. Copies are available from the National Academy Press, 2101 Constitution Ave. NW., Washington, DC 20418, or available for inspection at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
( c ) In accordance with § 184.1(b)(1), the ingredient is used in food with no limitation other than current good manufacturing practice. The affirmation of this ingredient as generally recognized as safe (GRAS) as a direct human food ingredient is based upon the following current good manufacturing practice conditions of use: ( 1 ) The ingredient is used as a firming agent as defined in § 170.3(o)(10) of this chapter; a flavor enhancer as defined in § 170.3(o)(11) of this chapter; a flavoring agent as defined in § 170.3(o)(12) of this chapter; a humectant as defined in § 170.3(o)(16) of this chapter; and a pH control agent as defined in § 170.3(o)(23) of this chapter.
( 2 ) The ingredient is used in foods at levels not to exceed current good manufacturing practice.
( d ) Prior sanctions for this ingredient different from the uses established in this section do not exist or have been waived.
[48 FR 52447, Nov. 18, 1983, as amended at 50 FR 49536, Dec. 3, 1985]
<PAGE>   1
                                                                    EXHIBIT 10.4



                            APPROVAL BY DIRECTORS OF
                           PUGET SOUND BANCORP, INC.


         The undersigned, all of the members of the Board of Directors of Puget
Sound Bancorp, Inc. (the "Company"), approve the foregoing Plan and, except as
otherwise required by applicable law, including without limitation their
fiduciary duties to the Company's shareholders, agree to (a) vote their shares
in favor of the transactions contemplated by the Plan, (b) recommend to the
shareholders of the Company that they approve the Plan, and (c) refrain from
any actions or omissions inconsistent with such transactions or recommendation.


          /s/                                         /s/
-------------------------------            -------------------------------
William D. Bloomquist                      Thomas O. Myers

          /s/                                         /s/
-------------------------------            -------------------------------
Donald F. Cox                              Kenneth F. Paskett

          /s/                                         /s/
-------------------------------            -------------------------------
Richard L. Granquist                       David C. Burgett

          /s/                                         /s/
-------------------------------            -------------------------------
Duane R. Guggenmos                         Jeffrey L. Swan

          /s/                                         /s/
-------------------------------            -------------------------------
Charles P. Hensen                          D. Alson VanderStaay

          /s/                         
-------------------------------       
Donald L. Morrison


Dated as of September 18, 1997
<PAGE>   1
                                                                    EXHIBIT 10.3

                              DIRECTOR'S AGREEMENT

         This Agreement is made and entered into as of the ____ day of
___________, 1997, between INTERWEST BANCORP, INC., a Washington corporation
("InterWest") and _____________________ ("Director"), a director of Puget Sound
Bancorp, Inc. (the "Company").

                                    RECITALS

         1.      Pursuant to the terms of the Agreement and Plan of Merger
dated as of the 18th day of September, 1997 (the "Plan") among InterWest, its
wholly owned subsidiary InterWest Bank, the Company and its wholly owned
subsidiary, First National Bank of Port Orchard ("Port Orchard Bank"), the
Company will be merged into InterWest, and Port Orchard Bank will become the
wholly owned subsidiary of InterWest.

         2.      The obligation of InterWest and InterWest Bank to consummate
the transactions contemplated by the Plan is conditioned upon their receipt of
non-competition agreements from directors of the Company and Port Orchard Bank.

         3.      Director is a shareholder of the Company in addition to
occupying the position of Director.

                                   AGREEMENT

         In consideration of the performance of InterWest and InterWest Bank
under the Plan, Director agrees that for a period of three (3) years after the
Effective Date, as defined in the Plan, he will not, directly or indirectly,
become interested in, as a principal shareholder, director or officer of, any
financial institution that competes with InterWest or any of its subsidiaries
or their affiliates within Kitsap County in the State of Washington.

         For purposes of this Agreement, the term "principal shareholder" means
any person who owns, directly or indirectly, five percent (5%) or more of the
outstanding shares of any class of equity security of a company.

         Director recognizes and agrees that any breach of this Agreement by
Director will entitle InterWest and InterWest Bank and any of their successors
or assigns to injunctive relief and/or specific performance, as well as any
other legal or equitable remedies to which such entities may otherwise be
entitled.

Executed as of the ____ day of _____________, 1997.

INTERWEST BANCORP, INC.                         DIRECTOR

By: /s/                                          /s/ 
   ----------------------------                 ----------------------------
Its: 
    ---------------------------
#### § 1308.41 Hearings generally.

In any case where the Administrator shall hold a hearing on the issuance, amendment, or repeal of rules pursuant to section 201 of the Act, the procedures for such hearing and accompanying proceedings shall be governed generally by the rulemaking procedures set forth in the Administrative Procedure Act (5 U.S.C. 551-559) and specifically by section 201 of the Act (21 U.S.C. 811), by §§ 1308.42-1308.51, and by §§ 1316.41-1316.67 of this chapter.
Exhibit 31.1
 
 Certification:
 
 I, Gary D. Engle, certify that:
 
 1.I have reviewed this quarterly report on Form 10-QSB of Semele Group Inc;

2.Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

3.Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

4.The registrants other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and


5.The registrants other certifying officers and I have disclosed, based on our most recent evaluation of internal controls over financial reporting, to the registrants auditors and the audit committee of registrants board of directors (or persons performing the equivalent functions):

a)all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and

b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal controls over financial reporting.

6.The registrants other certifying officers and I have indicated in this quarterly report whether there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.
 /s/ Gary D. Engle
 Gary D. Engle
 Chairman and Chief Executive Officer
 (Principal Executive Officer)
 May 14, 2004
§ 1002.31 Preservation and inspection of records. ( a ) Every manufacturer required to maintain records pursuant to this part, including records received pursuant to § 1002.41, shall preserve such records for a period of 5 years from the date of the record.
( b ) Upon reasonable notice by an officer or employee duly designated by the Department, manufacturers shall permit such officer or employee to inspect appropriate books, records, papers, and documents as are relevant to determining whether the manufacturer has acted or is acting in compliance with Federal standards.
( c ) Upon request of the Director, Center for Devices and Radiological Health, a manufacturer of products listed in table 1 of § 1002.1 shall submit to the Director, copies of the records required to be maintained by paragraph (b) of § 1002.30.
[38 FR 28625, Oct. 15, 1973, as amended at 53 FR 11254, Apr. 6, 1988; 60 FR 48386, Sept. 19, 1995]
Editorial Note on Part 14
Editorial Note: Nomenclature changes to part 14 appear at 88 FR 45065, July 14, 2023.

§ 14.30 Chairperson of an advisory committee. ( a ) The advisory committee Chairperson has the authority to conduct hearings and meetings, including the authority to adjourn a hearing or meeting if the Chairperson determines that adjournment is in the public interest, to discontinue discussion of a matter, to conclude the open portion of a meeting, or to take any other action to further a fair and expeditious hearing or meeting.
( b ) If the Chairperson is not a full-time employee of FDA, the Designated Federal Officer or other designated agency employee, or alternate, is to be the *designated Federal employee* who is assigned to the advisory committee. The designated Federal employee is also authorized to adjourn a hearing or meeting if the employee determines adjournment to be in the public interest.
<PAGE>   1
                                                                    EXHIBIT 23.2




                       CONSENT OF INDEPENDENT ACCOUNTANTS


We consent to the incorporation by reference in the Registration Statement
(Form S-8 No. 333-07549) pertaining to the BT Office Products International,
Inc. 1995 Stock Option Plan and the Non-Qualified Stock Option Agreement
between BT Office Products International, Inc. and Herman C. Brauckmann of our
report dated April 5, 1996, with respect to the consolidated financial
statements and schedule of BT Office Products International, Inc. included in
the Annual Report on Form 10-K for the year ended December 31, 1997.




                                                        Ernst & Young LLP


Chicago, Illinois
March 24, 1998
###### Editorial Note on Part 180

#### Editorial Note:

Nomenclature changes to part 180 appear at 79 FR 75879, Dec. 19, 2014.

#### § 180.945 System for Award Management Exclusions (SAM Exclusions).

*System for Award Management Exclusions (SAM Exclusions)* means the list maintained and disseminated by the General Services Administration (GSA) containing the names and other information about persons who are ineligible.

[79 FR 75880, Dec. 19, 2014]
§ 121.157 Reanalysis. ( a ) You must conduct a reanalysis of the food defense plan, as a whole at least once every 3 years;
( b ) You must conduct a reanalysis of the food defense plan as a whole, or the applicable portion of the food defense plan: ( 1 ) Whenever a significant change made in the activities conducted at your facility creates a reasonable potential for a new vulnerability or a significant increase in a previously identified vulnerability;
( 2 ) Whenever you become aware of new information about potential vulnerabilities associated with the food operation or facility;
( 3 ) Whenever you find that a mitigation strategy, a combination of mitigation strategies, or the food defense plan as a whole is not properly implemented; and
( 4 ) Whenever FDA requires reanalysis to respond to new vulnerabilities, credible threats to the food supply, and developments in scientific understanding including, as appropriate, results from the Department of Homeland Security biological, chemical, radiological, or other terrorism risk assessment.
( c ) You must complete such reanalysis required by paragraphs (a) and (b) of this section and implement any additional mitigation strategies needed to address the significant vulnerabilities identified, if any: ( 1 ) Before any change in activities (including any change in mitigation strategy) at the facility is operative;
( 2 ) When necessary within 90-calendar days after production; and
( 3 ) Within a reasonable timeframe, providing a written justification is prepared for a timeframe that exceeds 90 days after production of the applicable food first begins.
( d ) You must revise the written food defense plan if a significant change in the activities conducted at your facility creates a reasonable potential for a new vulnerability or a significant increase in a previously identified vulnerability or document the basis for the conclusion that no revisions are needed.
Editorial Note on Part 170
Editorial Note: Nomenclature changes to part 170 appear at 66 FR 56035, Nov. 6, 2001, and 69 FR 13717, Mar. 24, 2004.

§ 170.100 Submission of a premarket notification for a food contact substance (FCN) to the Food and Drug Administration (FDA). ( a ) An FCN is effective for the food contact substance manufactured or prepared by the manufacturer or supplier identified in the FCN submission. If another manufacturer or supplier wishes to market the same food contact substance for the same use, that manufacturer or supplier must also submit an FCN to FDA. ( 1 ) An FCN must contain all of the information described in § 170.101.
( 2 ) An FCN may incorporate by reference any information in FDA's files provided that the manufacturer or supplier is authorized to reference the information. The FCN must include information establishing that the manufacturer or supplier is authorized to reference information in FDA's files.
( 3 ) Any material submitted in or referenced by an FCN that is in a foreign language must be accompanied by an English translation verified to be complete and accurate.
( b ) FDA may choose not to accept an FCN for either of the following: ( 1 ) A use of a food contact substance that is the subject of a regulation in parts 173 through 189 of this chapter; or
( 2 ) A use of a food contact substance that is the subject of an exemption under the threshold of regulation process described in § 170.39.
( c ) A petition must be submitted under § 171.1 of this chapter to authorize the safe use of a food contact substance in either of the following circumstances, unless FDA agrees to accept an FCN for the proposed use. ( 1 ) The use of the food contact substance increases the cumulative dietary concentration to a certain level. For a substance that is a biocide (e.g., it is intended to exert microbial toxicity), this level is equal to or greater than 200 parts per billion in the daily diet (0.6 milligram (mg)/person/day). For a substance that is not a biocide, this level is equal to or greater than 1 part per million in the daily diet (3 mg/person/day); or
( 2 ) There exists a bioassay on the food contact substance, FDA has not reviewed the bioassay, and the bioassay is not clearly negative for carcinogenic effects.
( d ) A manufacturer or supplier for which a notification is effective must keep a current address on file with FDA. ( 1 ) The current address may be either the manufacturer's (or supplier's) address or the address of the manufacturer's (or supplier's) agent.
( 2 ) FDA will deliver correspondence to the manufacturer's or supplier's current address.
| (logo) WELLS FARGO | **Corporate Trust Services**MAC R1204-0109062 Old Annapolis RoadColumbia, MD 21045Tel: 410 884 2000 Fax: 410 715 2380 |
|--------------------|-----------------------------------------------------------------------------------------------------------------------|

 

 

Deutsche Mortgage & Asset Receiving Corporation 

60 WALL ST

NEW YORK, New York 10005-2836

 

 

RE: Annual Statement of Compliance for Deutsche Mortgage & Asset Receiving Corporation, Commercial Mortgage Pass- Through Certificates, Series 2013- CCRE7

 

Per the Pooling and Servicing Agreement dated as of April 1, 2013 (the "Agreement"), the undersigned, a duly authorized officer of Wells Fargo Bank, N.A., as Certificate Administrator ("Wells Fargo"), hereby certifies as follows as of and for the year ending December 31, 2015 (the "Reporting Period"):

 

(a) A review of Wells Fargo's activities during the Reporting Period and of its performance under the Agreement has been made under such officer's supervision; and

 

(b) To the best of such officer's knowledge, based on such review, Wells Fargo has fulfilled all of its obligations under the Agreement in all material respects throughout the Reporting Period.

 

 

March 1, 2016

 

 

/s/ Brian Smith

BRIAN SMITH

Vice President

 

 

Wells Fargo Bank, N.A.
§ 801.1111 Notice. ( a ) *Generally.* A limited denial of participation shall be initiated by advising a participant or contractor, and any specifically named affiliate, by certified mail, return receipt requested: ( 1 ) That the sanction is effective as of the date of the notice;
( 2 ) Of the reasons for the sanction in terms sufficient to put the participant or contractor on notice of the conduct or transaction(s) upon which it is based;
( 3 ) Of the cause(s) relied upon under § 801.1105 for imposing the sanction;
( 4 ) Of the right to request in writing, within 30 days of receipt of the notice, a conference on the sanction, and the right to have such conference held within 10 business days of receipt of the request;
( 5 ) Of the potential effect of the sanction and the impact on the participant's or contractor's participation in Departmental programs, specifying the program(s) involved and the geographical area affected by the action.
( b ) *Notification of action.* After 30 days, if no conference has been requested, the official imposing the limited denial of participation will notify VA Central Office of the action taken and of the fact that no conference has been requested. If a conference is requested within the 30-day period, VA Central Office need not be notified unless a decision to affirm all or a portion of the remaining period of exclusion is issued. VA Central Office will notify all VA field offices of sanctions imposed and still in effect under this subpart.
sourceTypeID isLeapYear monthID monthVMTFraction

11 Y 1 0.0729041

11 Y 2 0.072023

11 Y 3 0.0815285

11 Y 4 0.0820979

11 Y 5 0.0872855

11 Y 6 0.0880524

11 Y 7 0.0920958

11 Y 8 0.0931976

11 Y 9 0.0844703

11 Y 10 0.0863011

11 Y 11 0.080029

11 Y 12 0.0800148

21 Y 1 0.0729041

21 Y 2 0.072023

21 Y 3 0.0815285

21 Y 4 0.0820979

21 Y 5 0.0872855

21 Y 6 0.0880524

21 Y 7 0.0920958

21 Y 8 0.0931976

21 Y 9 0.0844703

21 Y 10 0.0863011

21 Y 11 0.080029

21 Y 12 0.0800148

31 Y 1 0.0729041

31 Y 2 0.072023

31 Y 3 0.0815285

31 Y 4 0.0820979

31 Y 5 0.0872855

31 Y 6 0.0880524

31 Y 7 0.0920958

31 Y 8 0.0931976

31 Y 9 0.0844703

31 Y 10 0.0863011

31 Y 11 0.080029

31 Y 12 0.0800148

32 Y 1 0.0729041

32 Y 2 0.072023

32 Y 3 0.0815285

32 Y 4 0.0820979

32 Y 5 0.0872855

32 Y 6 0.0880524

32 Y 7 0.0920958

32 Y 8 0.0931976

32 Y 9 0.0844703

32 Y 10 0.0863011

32 Y 11 0.080029

32 Y 12 0.0800148

41 Y 1 0.0729041

41 Y 2 0.072023

41 Y 3 0.0815285
41

Y4 0.0820979

41Y5 0.0872855

41Y6 0.0880524

41Y7 0.0920958

41Y8 0.0931976

41Y9 0.0844703

41Y 10 0.0863011

41Y 11 0.080029

41Y 12 0.0800148

42Y1 0.0729041

42Y2 0.072023

42Y3 0.0815285

42Y4 0.0820979

42Y5 0.0872855

42Y6 0.0880524

42Y7 0.0920958

42Y8 0.0931976

42Y9 0.0844703

42Y 10 0.0863011

42Y 11 0.080029

42Y 12 0.0800148

43Y1 0.0729041

43Y2 0.072023

43Y3 0.0815285

43Y4 0.0820979

43Y5 0.0872855

43Y6 0.0880524

43Y7 0.0920958

43Y8 0.0931976

43Y9 0.0844703

43Y 10 0.0863011

43Y 11 0.080029

43Y 12 0.0800148

51Y1 0.0729041

51Y2 0.072023

51Y3 0.0815285

51Y4 0.0820979

51Y5 0.0872855

51Y6 0.0880524

51Y7 0.0920958

51Y8 0.0931976

51Y9 0.0844703

51Y 10 0.0863011

51Y 11 0.080029

51Y 12 0.0800148

52Y1 0.0729041

52Y2 0.072023

52Y3 0.0815285

52Y4 0.0820979

52Y5 0.0872855

52Y6 0.0880524

52Y7 0.0920958
52

Y8 0.0931976

52Y9 0.0844703

52Y 10 0.0863011

52Y 11 0.080029

52Y 12 0.0800148

53Y1 0.0729041

53Y2 0.072023

53Y3 0.0815285

53Y4 0.0820979

53Y5 0.0872855

53Y6 0.0880524

53Y7 0.0920958

53Y8 0.0931976

53Y9 0.0844703

53Y 10 0.0863011

53Y 11 0.080029

53Y 12 0.0800148

54Y1 0.0729041

54Y2 0.072023

54Y3 0.0815285

54Y4 0.0820979

54Y5 0.0872855

54Y6 0.0880524

54Y7 0.0920958

54Y8 0.0931976

54Y9 0.0844703

54Y 10 0.0863011

54Y 11 0.080029

54Y 12 0.0800148

61Y1 0.0729041

61Y2 0.072023

61Y3 0.0815285

61Y4 0.0820979

61Y5 0.0872855

61Y6 0.0880524

61Y7 0.0920958

61Y8 0.0931976

61Y9 0.0844703

61Y 10 0.0863011

61Y 11 0.080029

61Y 12 0.0800148

62Y1 0.0729041

62Y2 0.072023

62Y3 0.0815285

62Y4 0.0820979

62Y5 0.0872855

62Y6 0.0880524

62Y7 0.0920958

62Y8 0.0931976

62Y9 0.0844703

62Y 10 0.0863011

62Y 11 0.080029
62 Y 12 0.0800148
```

[Congressional Bills 109th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 902 Engrossed in House (EH)]

H. Res. 902

                 In the House of Representatives, U.S.,

                                                         June 29, 2006.
    Resolved, That the following named Member be, and he is hereby, elected to 
the following standing committees of the House of Representatives:
    Committee on Armed Services: Mr. Bilbray.
    Committee on Government Reform: Mr. Bilbray.
    Committee on Veterans' Affiars: Mr. Bilbray.

            Attest:

                                                                 Clerk.
```